X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs MERCK LTD - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA MERCK LTD ASTRAZENECA PHARMA/
MERCK LTD
 
P/E (TTM) x 94.8 25.9 365.5% View Chart
P/BV x 13.5 2.9 465.1% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 ASTRAZENECA PHARMA   MERCK LTD
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
MERCK LTD
Dec-16
ASTRAZENECA PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1,2851,060 121.2%   
Low Rs634623 101.8%   
Sales per share (Unadj.) Rs189.6632.4 30.0%  
Earnings per share (Unadj.) Rs-0.245.7 -0.4%  
Cash flow per share (Unadj.) Rs3.862.3 6.2%  
Dividends per share (Unadj.) Rs011.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs68.6388.8 17.7%  
Shares outstanding (eoy) m25.0016.60 150.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.11.3 380.4%   
Avg P/E ratio x-4,712.718.4 -25,602.9%  
P/CF ratio (eoy) x249.613.5 1,848.2%  
Price / Book Value ratio x14.02.2 645.9%  
Dividend payout %024.1 0.0%   
Avg Mkt Cap Rs m23,98813,969 171.7%   
No. of employees `0001.61.6 98.5%   
Total wages/salary Rs m1,6051,487 107.9%   
Avg. sales/employee Rs Th3,040.26,631.9 45.8%   
Avg. wages/employee Rs Th1,029.2939.2 109.6%   
Avg. net profit/employee Rs Th-3.3479.4 -0.7%   
INCOME DATA
Net Sales Rs m4,74010,498 45.1%  
Other income Rs m92242 38.0%   
Total revenues Rs m4,83210,741 45.0%   
Gross profit Rs m-1301,135 -11.4%  
Depreciation Rs m101276 36.7%   
Interest Rs m00-   
Profit before tax Rs m-1391,102 -12.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5343 1.5%   
Profit after tax Rs m-5759 -0.7%  
Gross profit margin %-2.710.8 -25.3%  
Effective tax rate %-3.731.1 -11.8%   
Net profit margin %-0.17.2 -1.5%  
BALANCE SHEET DATA
Current assets Rs m2,7266,410 42.5%   
Current liabilities Rs m2,4358,828 27.6%   
Net working cap to sales %6.1-23.0 -26.7%  
Current ratio x1.10.7 154.2%  
Inventory Days Days7458 127.9%  
Debtors Days Days4138 106.2%  
Net fixed assets Rs m1,0351,406 73.6%   
Share capital Rs m50166 30.1%   
"Free" reserves Rs m9426,286 15.0%   
Net worth Rs m1,7166,455 26.6%   
Long term debt Rs m00-   
Total assets Rs m4,1568,828 47.1%  
Interest coverage xNMNM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.11.2 95.9%   
Return on assets %-0.18.6 -1.4%  
Return on equity %-0.311.8 -2.5%  
Return on capital %017.1 0.0%  
Exports to sales %5.78.3 68.8%   
Imports to sales %6.521.0 30.7%   
Exports (fob) Rs m270869 31.1%   
Imports (cif) Rs m3062,209 13.9%   
Fx inflow Rs m375959 39.1%   
Fx outflow Rs m4702,612 18.0%   
Net fx Rs m-96-1,653 5.8%   
CASH FLOW
From Operations Rs m-81,070 -0.8%  
From Investments Rs m-146-750 19.4%  
From Financial Activity Rs m862-150 -575.6%  
Net Cashflow Rs m709171 414.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.8 144.8%  
Indian inst/Mut Fund % 0.3 18.2 1.6%  
FIIs % 15.7 1.0 1,570.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 29.1 31.3%  
Shareholders   12,856 28,591 45.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  FDC LTD.  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 17, 2017 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS